Abstract
Most patients with hypertension will require treatment with at least two antihypertensive agents to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combination (SPC) therapy in patients with mild-to-moderate hypertension who are inadequately responsive to amlodipine monotherapy. Patients with mean sitting diastolic BP (msDBP) ≥ 90 and < 110 mmHg after 4 weeks’ treatment with amlodipine 10 mg were randomized to once-daily aliskiren/amlodipine 300/10 mg (n = 279) or 150/10 mg (n = 285) or amlodipine 10 mg monotherapy (n = 283) for 8 weeks. Aliskiren/amlodipine 300/10 and 150/10 mg SPCs provided significantly greater reductions in mean sitting systolic BP/msDBP (14.4/11.0 and 11.0/9.0 mmHg, respectively) than amlodipine 10 mg (8.2/7.2 mmHg) at week 8 endpoint. This represents additional mean reductions of 6.2/3.8 mmHg (300/10 mg) and 2.8/1.7 mmHg (150/10 mg) over amlodipine alone (all P < 0.01). Significantly more patients achieved BP control (< 140/90 mmHg) with aliskiren/amlodipine 300/10 mg (58.8%) than amlodipine 10 mg (38.4%; P < 0.0001). Aliskiren/amlodipine SPCs were generally well tolerated. In conclusion, aliskiren/amlodipine SPCs offers an effective option for management of patients who have an inadequate BP response to amlodipine alone.
Keywords: Aliskiren, amlodipine, single pill combination, hypertension, non- responder
Current Vascular Pharmacology
Title:Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥
Volume: 10 Issue: 6
Author(s): Dietrich Pfeiffer, Nicola Rennie, Cheraz C. Papst and Jack Zhang
Affiliation:
Keywords: Aliskiren, amlodipine, single pill combination, hypertension, non- responder
Abstract: Most patients with hypertension will require treatment with at least two antihypertensive agents to achieve blood pressure (BP) control. This double-blind study evaluated the efficacy and safety of aliskiren/amlodipine single-pill combination (SPC) therapy in patients with mild-to-moderate hypertension who are inadequately responsive to amlodipine monotherapy. Patients with mean sitting diastolic BP (msDBP) ≥ 90 and < 110 mmHg after 4 weeks’ treatment with amlodipine 10 mg were randomized to once-daily aliskiren/amlodipine 300/10 mg (n = 279) or 150/10 mg (n = 285) or amlodipine 10 mg monotherapy (n = 283) for 8 weeks. Aliskiren/amlodipine 300/10 and 150/10 mg SPCs provided significantly greater reductions in mean sitting systolic BP/msDBP (14.4/11.0 and 11.0/9.0 mmHg, respectively) than amlodipine 10 mg (8.2/7.2 mmHg) at week 8 endpoint. This represents additional mean reductions of 6.2/3.8 mmHg (300/10 mg) and 2.8/1.7 mmHg (150/10 mg) over amlodipine alone (all P < 0.01). Significantly more patients achieved BP control (< 140/90 mmHg) with aliskiren/amlodipine 300/10 mg (58.8%) than amlodipine 10 mg (38.4%; P < 0.0001). Aliskiren/amlodipine SPCs were generally well tolerated. In conclusion, aliskiren/amlodipine SPCs offers an effective option for management of patients who have an inadequate BP response to amlodipine alone.
Export Options
About this article
Cite this article as:
Pfeiffer Dietrich, Rennie Nicola, C. Papst Cheraz and Zhang Jack, Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy¥, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520945
DOI https://dx.doi.org/10.2174/157016112803520945 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
X-Ray Versus Magnetic Resonance Imaging in Diabetic Foot Osteomyelitis: A Clinical Comparison
Current Diabetes Reviews Acute Coronary Syndromes: A Role of Immune System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design Enzymatic regulation and functional relevance of NOX5
Current Pharmaceutical Design Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Drugs in Pediatric Ischemic Stroke
Current Drug Targets New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry